Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II) Stanley Szefler, Jonathan Corren, Jonathan I. Silverberg, Angela Okragly, Zhe Sun, Chitra R. Natalie, show all Pages 1211-1216 | Received 06 Au...
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II):replicate,phase 3,randomised,double-blind,placebo-controlled trials. Hanania NA,Korenblat P,Chapman KR,et al. Lancet Respir Med . 2016Hanania, N. A., Korenblat, P., Chapman...
Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428. xvii Munera-Campos M, et al. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment. Actas Dermosifilio...
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781-796. doi:10.1016/S2213-2600(16)30265-X PubMedGoogle ScholarCrossref 47. ...
Lebrikizumab, tralokinumab, and dupilumab are 3 monoclonal antibodies that can inhibit the IL-13 pathway in asthma and allergic disease. Lebrikizumab is a humanized IgG4 monoclonal antibody that specifically binds to IL-13 and inhibits its function.72 In an initial phase 2 randomized, placebo-...
Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428. Munera-Campos M, et al. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment. Actas Dermosifiliogr. 2020;111(3):205-221. ...
The NMA included randomized, double-blind, placebo-controlled monotherapy phase 2 and 3 trials of biologics (lebrikizumab 250 mg every 2 weeks [Q2W], dupilumab 300 mg Q2W, and tralokinumab 300 mg Q2W) and JAK inhibitors (abrocitinib 100/200 mg daily, baricitinib 2/4 mg daily, and up...
Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppresive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. It has successfully completed a Phase II clinical trial. Lebrikizumab blocks interleukin 13 (IL-13), a ...
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-... SummaryBackground In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation rates and improved FEV1...
(KGAF). In these 4 trials, mean age was 37 years; 50% of subjects were male; 62% were White, 13% were Black, and 20% were Asian. In terms of co-morbid conditions, in the phase 3 trials, 30% of the subjects hadasthma, 50% hadallergic rhinitis, 31% had foodallergy, and 14% ...